Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 17

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 17
---
 Placement Agent may be required to make in respect thereof.

Fees and Expenses

We
have engaged A.G.P. as our sole placement agent in connection with this offering. This offering is being conducted on a “reasonable
best efforts” basis and the Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase
or sale of any specific number or dollar amount of securities. We have agreed to pay the Placement Agent a fee based on the aggregate
proceeds as set forth in the table below.

|                                 |     | Per Share |       |     | Total |               |
|:--------------------------------|:----|:----------|------:|:----|:------|--------------:|
| Offering price                  |     | $         |  6.30 |     | $     | 18,900,000.00 |
| Placement Agent fees (1)        |     | $         | 0.441 |     | $     |    1,323, 000 |
| Proceeds, before expenses to us |     | $         | 5.859 |     | $     |    17,577,000 |

| (1) | We have agreed to pay the Placement Agent a cash fee of 7.0% of the aggregate gross proceeds raised in connection with the offering. We have also agreed to reimburse the Placement Agent for certain of its expenses in an amount up to $75,000. |

We
estimate the total expenses payable by us for this offering, excluding the Placement Agent’s fee and expenses, will be approximately
$150,000.

The
Placement Agent may be deemed to be underwriters within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received
by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting discounts
or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the
Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation
M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the Placement Agent acting
as principal. Under these rules and regulations, the Placement Agent:

| ● | may not engage in any stabilization activity in connection 
 with our securities; and                                   |

|